SlideShare una empresa de Scribd logo
1 de 36
Oligonucleotide Therapeutics: Basic Principles and Delivery Strategies Ashish Sarode February 17, 2006
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
Definitions ,[object Object],[object Object]
Past and Present 1,2 ,[object Object],[object Object],[object Object]
Current Research 3 Isis Pharmaceuticals 2003 annual report
Clinical Trials 4 Isis Pharmaceuticals 2004 annual report
[object Object]
Gene Therapy vs. ON Therapy 5 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Modulation of gene expression 2,6 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antisense Technology 6 ,[object Object],J. Dagle, D Weeks 2001
Antisense Technology 7 E. Devor 2005
Antigene Technology 6 J. Dagle, D Weeks 2001
Antigene Technology 8 ,[object Object],[object Object],R. Guntaka, B. Varma, K. Webber2003
Antigene Technology 2 S. Buchini, C. Leumann 2003
Antisense vs. Antigene 2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],S. Buchini, C. Leumann 2003
Steps in successful ON therapy 9 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Designing ONs 9 ,[object Object],[object Object],[object Object],S. Akhtar 2000
Stability 2 ,[object Object],S. Buchini, C. Leumann 2003
[object Object]
Delivery Strategies 9 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Liposomes 10 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Anionic Liposomes ,[object Object],[object Object],[object Object],[object Object],O. Zelphati, F. Szoka1996
pH-sensitive Liposomes ,[object Object],[object Object],[object Object],[object Object],[object Object],O. Zelphati, F. Szoka1996
Immunoliposomes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],O. Zelphati, F. Szoka1996
Fusogenic Liposomes ,[object Object],[object Object],[object Object],[object Object],[object Object],O. Zelphati, F. Szoka1996
Cationic Liposomes ,[object Object],[object Object],[object Object],[object Object],O. Zelphati, F. Szoka1996
Cationic Liposomes O. Zelphati, F. Szoka1996
Dendrimers 9 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Carrier peptide-mediated 5,9 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Receptor-mediated 5 ,[object Object],[object Object],Y. Rojanasakul 1996
Polymers 9 ,[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object]
References ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Acknowledgement ,[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Antisense oligonucleotide therapy
Antisense oligonucleotide therapyAntisense oligonucleotide therapy
Antisense oligonucleotide therapyROHIT
 
Antisense oligoneucleotides in therapy
Antisense  oligoneucleotides  in therapyAntisense  oligoneucleotides  in therapy
Antisense oligoneucleotides in therapyDr Sajeena Jose
 
De novo drug design
De novo drug designDe novo drug design
De novo drug designmojdeh y
 
Antisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotidesAntisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotidesRangnathChikane
 
Recombinant DNA Technology and Drug Discovery
Recombinant DNA Technology and Drug DiscoveryRecombinant DNA Technology and Drug Discovery
Recombinant DNA Technology and Drug DiscoveryDivya V
 
ZINC FINGER PROTEIN.pptx
ZINC FINGER PROTEIN.pptxZINC FINGER PROTEIN.pptx
ZINC FINGER PROTEIN.pptxShobhiniChandel
 
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)Satigayatri
 
Recombinant DNA Technology & Gene Therapy
Recombinant DNA Technology & Gene TherapyRecombinant DNA Technology & Gene Therapy
Recombinant DNA Technology & Gene TherapyAshitoshPanchal
 
Virtual screening techniques
Virtual screening techniquesVirtual screening techniques
Virtual screening techniquesROHIT PAL
 
Molecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentationMolecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentationHarendra Bisht
 
(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptx(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptxKartik Tiwari
 
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESayanarkumar19
 

La actualidad más candente (20)

Antisense oligonucleotide therapy
Antisense oligonucleotide therapyAntisense oligonucleotide therapy
Antisense oligonucleotide therapy
 
Antisense oligoneucleotides in therapy
Antisense  oligoneucleotides  in therapyAntisense  oligoneucleotides  in therapy
Antisense oligoneucleotides in therapy
 
De novo drug design
De novo drug designDe novo drug design
De novo drug design
 
Oligonucleotide
OligonucleotideOligonucleotide
Oligonucleotide
 
Antisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotidesAntisense technologies and antisense oligonucleotides
Antisense technologies and antisense oligonucleotides
 
Recombinant DNA Technology and Drug Discovery
Recombinant DNA Technology and Drug DiscoveryRecombinant DNA Technology and Drug Discovery
Recombinant DNA Technology and Drug Discovery
 
Aptamer as therapeutic
Aptamer as therapeuticAptamer as therapeutic
Aptamer as therapeutic
 
ZINC FINGER PROTEIN.pptx
ZINC FINGER PROTEIN.pptxZINC FINGER PROTEIN.pptx
ZINC FINGER PROTEIN.pptx
 
2D - QSAR
2D - QSAR2D - QSAR
2D - QSAR
 
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
QSAR statistical methods for drug discovery(pharmacology m.pharm2nd sem)
 
Oligonucleotides
Oligonucleotides Oligonucleotides
Oligonucleotides
 
Recombinant DNA Technology & Gene Therapy
Recombinant DNA Technology & Gene TherapyRecombinant DNA Technology & Gene Therapy
Recombinant DNA Technology & Gene Therapy
 
Peptidomimitics
PeptidomimiticsPeptidomimitics
Peptidomimitics
 
Virtual screening techniques
Virtual screening techniquesVirtual screening techniques
Virtual screening techniques
 
Molecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentationMolecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentation
 
Virtual sreening
Virtual sreeningVirtual sreening
Virtual sreening
 
Oligonucleotides
OligonucleotidesOligonucleotides
Oligonucleotides
 
(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptx(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptx
 
CADD
CADDCADD
CADD
 
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDES
 

Destacado

Nucleic acids as therapeutic agents
Nucleic acids as therapeutic agentsNucleic acids as therapeutic agents
Nucleic acids as therapeutic agentsRESHMASOMAN3
 
Aptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic Use
Aptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic UseAptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic Use
Aptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic Useajithnandanam
 
Oligonucleotide synthesis - Problems and Challenges
Oligonucleotide synthesis - Problems and ChallengesOligonucleotide synthesis - Problems and Challenges
Oligonucleotide synthesis - Problems and Challengesajithnandanam
 
Oligonucleotide Therapeutics: Brief Overview of the State of the Market
Oligonucleotide Therapeutics: Brief Overview of the State of the MarketOligonucleotide Therapeutics: Brief Overview of the State of the Market
Oligonucleotide Therapeutics: Brief Overview of the State of the MarketPeter Dellva
 
Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...
Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...
Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...Ashwini Gi
 
Sujiko plan marketing
Sujiko plan marketingSujiko plan marketing
Sujiko plan marketingSarif Salleh
 
Viral Gene Therapy ''Multiple Sclerosis'' by Farshid Mokhberi
Viral Gene Therapy ''Multiple Sclerosis''  by Farshid MokhberiViral Gene Therapy ''Multiple Sclerosis''  by Farshid Mokhberi
Viral Gene Therapy ''Multiple Sclerosis'' by Farshid MokhberiFarshid Mokhberi
 
AGRCARTRADE - KERETA MUDAH MILIK
AGRCARTRADE - KERETA MUDAH MILIKAGRCARTRADE - KERETA MUDAH MILIK
AGRCARTRADE - KERETA MUDAH MILIKSarif Salleh
 
Antisense rna and dna
Antisense rna and dnaAntisense rna and dna
Antisense rna and dnaErin Sharkawy
 
Cubic Phase Nanoparticles
Cubic Phase NanoparticlesCubic Phase Nanoparticles
Cubic Phase Nanoparticlesasarode
 
Bilingüismo en la ESO - Comunidad de Madrid
Bilingüismo en la ESO - Comunidad de MadridBilingüismo en la ESO - Comunidad de Madrid
Bilingüismo en la ESO - Comunidad de MadridRaquel TM
 
Escoitar.org por Chiu Longina
Escoitar.org por Chiu LonginaEscoitar.org por Chiu Longina
Escoitar.org por Chiu LonginaChiu Longina
 
Sintesis informativa julio 03 2013
Sintesis informativa julio 03 2013Sintesis informativa julio 03 2013
Sintesis informativa julio 03 2013megaradioexpress
 

Destacado (20)

Nucleic acids as therapeutic agents
Nucleic acids as therapeutic agentsNucleic acids as therapeutic agents
Nucleic acids as therapeutic agents
 
Antisense therapy
Antisense therapyAntisense therapy
Antisense therapy
 
Aptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic Use
Aptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic UseAptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic Use
Aptamers - New Class of Oligonucleotide for Therapeutic and Diagnostic Use
 
Oligonucleotide synthesis - Problems and Challenges
Oligonucleotide synthesis - Problems and ChallengesOligonucleotide synthesis - Problems and Challenges
Oligonucleotide synthesis - Problems and Challenges
 
Antisense therapy
Antisense therapyAntisense therapy
Antisense therapy
 
antisense technology
antisense technologyantisense technology
antisense technology
 
Oligonucleotide Therapeutics: Brief Overview of the State of the Market
Oligonucleotide Therapeutics: Brief Overview of the State of the MarketOligonucleotide Therapeutics: Brief Overview of the State of the Market
Oligonucleotide Therapeutics: Brief Overview of the State of the Market
 
Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...
Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...
Antisense oligonucleotides-therapy-in-the-treatment-of-cerebral-gliomas-a-rev...
 
Sujiko plan marketing
Sujiko plan marketingSujiko plan marketing
Sujiko plan marketing
 
Viral Gene Therapy ''Multiple Sclerosis'' by Farshid Mokhberi
Viral Gene Therapy ''Multiple Sclerosis''  by Farshid MokhberiViral Gene Therapy ''Multiple Sclerosis''  by Farshid Mokhberi
Viral Gene Therapy ''Multiple Sclerosis'' by Farshid Mokhberi
 
AGRCARTRADE - KERETA MUDAH MILIK
AGRCARTRADE - KERETA MUDAH MILIKAGRCARTRADE - KERETA MUDAH MILIK
AGRCARTRADE - KERETA MUDAH MILIK
 
Antisense rna and dna
Antisense rna and dnaAntisense rna and dna
Antisense rna and dna
 
Cubic Phase Nanoparticles
Cubic Phase NanoparticlesCubic Phase Nanoparticles
Cubic Phase Nanoparticles
 
AVS 406 Presentation
AVS 406 PresentationAVS 406 Presentation
AVS 406 Presentation
 
Bilingüismo en la ESO - Comunidad de Madrid
Bilingüismo en la ESO - Comunidad de MadridBilingüismo en la ESO - Comunidad de Madrid
Bilingüismo en la ESO - Comunidad de Madrid
 
Edebé
EdebéEdebé
Edebé
 
Arpimed Catalog
Arpimed CatalogArpimed Catalog
Arpimed Catalog
 
Transformadores
TransformadoresTransformadores
Transformadores
 
Escoitar.org por Chiu Longina
Escoitar.org por Chiu LonginaEscoitar.org por Chiu Longina
Escoitar.org por Chiu Longina
 
Sintesis informativa julio 03 2013
Sintesis informativa julio 03 2013Sintesis informativa julio 03 2013
Sintesis informativa julio 03 2013
 

Similar a Oligonucleotide Therapeutics

2014 09-10 ACI biomarker utilisation & commercialisation, London
2014 09-10 ACI biomarker utilisation & commercialisation, London2014 09-10 ACI biomarker utilisation & commercialisation, London
2014 09-10 ACI biomarker utilisation & commercialisation, LondonAlain van Gool
 
Drug discovery thr enzyme inhibition
Drug discovery thr enzyme inhibitionDrug discovery thr enzyme inhibition
Drug discovery thr enzyme inhibitionDr. Manoj Kumbhare
 
2014 10-15 LGC Biosciences Autumn seminar Cambridge
2014 10-15 LGC Biosciences Autumn seminar Cambridge2014 10-15 LGC Biosciences Autumn seminar Cambridge
2014 10-15 LGC Biosciences Autumn seminar CambridgeAlain van Gool
 
Target Validation Academy Of Medical Sciences 1 Dec 2006
Target Validation   Academy Of Medical Sciences 1 Dec 2006Target Validation   Academy Of Medical Sciences 1 Dec 2006
Target Validation Academy Of Medical Sciences 1 Dec 2006Mike Romanos
 
Pharmacology of lipid related diseases
Pharmacology of lipid related diseasesPharmacology of lipid related diseases
Pharmacology of lipid related diseasesRishi Sapkota
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphismBipul Das
 
Protein Engineering Strategies
Protein Engineering StrategiesProtein Engineering Strategies
Protein Engineering StrategiesSOURIKDEY1
 
EVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptx
EVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptxEVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptx
EVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptxDnyaneshwar Ningule
 
Protein and peptide delivery system
Protein and peptide delivery systemProtein and peptide delivery system
Protein and peptide delivery systemYamini Shah
 

Similar a Oligonucleotide Therapeutics (20)

2014 09-10 ACI biomarker utilisation & commercialisation, London
2014 09-10 ACI biomarker utilisation & commercialisation, London2014 09-10 ACI biomarker utilisation & commercialisation, London
2014 09-10 ACI biomarker utilisation & commercialisation, London
 
Drug discovery thr enzyme inhibition
Drug discovery thr enzyme inhibitionDrug discovery thr enzyme inhibition
Drug discovery thr enzyme inhibition
 
3targeting
3targeting3targeting
3targeting
 
2014 10-15 LGC Biosciences Autumn seminar Cambridge
2014 10-15 LGC Biosciences Autumn seminar Cambridge2014 10-15 LGC Biosciences Autumn seminar Cambridge
2014 10-15 LGC Biosciences Autumn seminar Cambridge
 
3targeting
3targeting3targeting
3targeting
 
liposomes.pptx
liposomes.pptxliposomes.pptx
liposomes.pptx
 
targeting
targetingtargeting
targeting
 
targeting
targetingtargeting
targeting
 
Opensourcepharma Dr Nibedita rath
Opensourcepharma Dr Nibedita rathOpensourcepharma Dr Nibedita rath
Opensourcepharma Dr Nibedita rath
 
Liposomes
LiposomesLiposomes
Liposomes
 
Liposomes
LiposomesLiposomes
Liposomes
 
Target Validation Academy Of Medical Sciences 1 Dec 2006
Target Validation   Academy Of Medical Sciences 1 Dec 2006Target Validation   Academy Of Medical Sciences 1 Dec 2006
Target Validation Academy Of Medical Sciences 1 Dec 2006
 
د. هدير ماهر
د. هدير ماهرد. هدير ماهر
د. هدير ماهر
 
Pharmacology of lipid related diseases
Pharmacology of lipid related diseasesPharmacology of lipid related diseases
Pharmacology of lipid related diseases
 
Pharmacogenetics
PharmacogeneticsPharmacogenetics
Pharmacogenetics
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
 
Presentation
PresentationPresentation
Presentation
 
Protein Engineering Strategies
Protein Engineering StrategiesProtein Engineering Strategies
Protein Engineering Strategies
 
EVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptx
EVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptxEVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptx
EVOLUTION OF DELIVERY SYSTEM OF PROTEIN AND OTHER MACROMOLECULES.pptx
 
Protein and peptide delivery system
Protein and peptide delivery systemProtein and peptide delivery system
Protein and peptide delivery system
 

Oligonucleotide Therapeutics